ORBIMED CAPITAL LLC
CIK 1157524 · last filed 2026-04-23
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$111.46M
Companies
7
Total Filings
33
Lifetime Open-Market Net
$39.06M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PRLD | Director | 1,126,126 | $4.68 | $5.27M | $65.00M | 3 | 2026-04-23 |
| SPRY | Director | 269,323 | $5.71 | $1.54M | -$3.26M | 1 | 2024-08-28 |
| Kinnate Biopharma Inc. (KNTE) Delisted | Director | 1,368,339 | $2.65 | $3.63M | $36.56M | 3 | 2023-05-08 |
| ARQT | Director | 3,534,537 | $28.43 | $100.49M | $43.84M | 3 | 2022-06-28 |
| PMVP | 10%+ Owner | 109,500 | $1.10 | $120.5K | -$41.06M | 1 | 2022-03-31 |
| Repare Therapeutics Inc. (RPTX) Delisted | Director | 3,221,637 | $2.65 | $8.54M | -$1.85M | 1 | 2021-08-30 |
| ALEC | Director | 2,650,781 | $1.52 | $4.04M | -$60.17M | 3 | 2019-12-26 |
Recent Filings · Page 2 of 4
33 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-10-02 | DMRA | Notice (144) | −57,312 | -$41.3K | EDGAR |
| 2023-08-30 | DMRA | Notice (144) | −119,679 | -$69.4K | EDGAR |
| 2023-08-21 | DMRA | Notice (144) | −147,910 | -$91.3K | EDGAR |
| 2023-08-15 | DMRA | Notice (144) | −114,843 | -$86.1K | EDGAR |
| 2023-07-31 | DMRA | Notice (144) | −246,830 | -$745.4K | EDGAR |
| 2023-07-25 | DMRA | Notice (144) | −8,100 | -$19.0K | EDGAR |
| 2023-07-13 | DMRA | Notice (144) | −14,700 | -$37.5K | EDGAR |
| 2023-06-15 | — | Notice (144) | −116,000 | -$664.7K | EDGAR |
| 2023-06-15 | — | Notice (144) | −205,000 | -$1.17M | EDGAR |
| 2023-06-12 | KROS | Notice (144) | −170,000 | -$7.46M | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.